Education
School — Major — Degree | Duration |
---|---|
高雄醫學大學 — 藥學系(畢) — 博士 Doctorate, School of Pharmacy, Kaohsiung Medical University |
2004/09 — 2009/01 |
長庚大學 — 中醫學系(畢) — 碩士 Master, Graduate Institute of Natural Products, Chang Gung University |
2002/06 — 2004/06 |
嘉南藥理大學 — 藥學系(畢) — 學士 Bachelor, Department of Pharmacy, Chia Nan University of Pharmacy & Science |
1999/09 — 2001/06 |
Intramural Experience
Office/Department/Institute | Position | Duration |
---|---|---|
藥學系 School of Pharmacy | Associate Professor | 2018/08/01 — |
藥學系 School of Pharmacy | Assistant Professor | 2014/08/01 — 2018/07/31 |
Extramural Experience
DEPNO | Position- Office/Department/Institute | Duration |
---|---|---|
元培科技大學 | 助理教授 | 0980801 — 1030731 |
Discipline
NO | Discipline | Expertise |
---|---|---|
1 | 生物醫農類 Biology, Medicine and Agriculture | 藥學及中醫藥 Pharmacy and Chinese Medicine and Pharmacy |
Research & Technology Platform Open to the Outside
Interested Area(s)for Interdisciplinary Research
生醫材料,化妝品劑型設計與功效評估
Area(s) of Expertise & Research
劑型設計,新穎奈米材料開發,藥物傳遞系統藥劑學,奈米醫學,藥物傳遞系統
Pharmaceutics, Nanomedicine, Drug delivery system
Publication
NO | Publication |
---|---|
1 | Maximizing Oxaliplatin's Impact on EGFR+ Colorectal Cancer Through Targeted Extracellular Vesicles Maximizing Oxaliplatin's Impact on EGFR+ Colorectal Cancer Through Targeted Extracellular Vesicles |
2 | 利用幾丁聚醣奈米膠囊纖維敷料應用於疏水/親水性藥物共同遞送應用在糖尿病傷口 Creation of Chitosan-Based Nanocapsule-in-Nanofiber Structures for Hydrophobic/Hydrophilic Drug Co-Delivery and Their Dressing Applications in Diabetic Wounds |
3 | 異甘草素通過葡萄糖調節蛋白 78 下調抑制胃癌幹細胞、調節腫瘤微環境和抑制腫瘤生長 Isoliquiritigenin Inhibits Gastric Cancer Stemness, Modulates Tumor Microenvironment, and Suppresses Tumor Growth through Glucose-Regulated Protein 78 Downregulation |
4 | Multifunctional TiO2/SBA-15 mesoporous silica hybrids loaded with organic sunscreens for skin application: The role in photoprotection and pollutant adsorption with reduced sunscreen permeation Multifunctional TiO2/SBA-15 mesoporous silica hybrids loaded with organic sunscreens for skin application: The role in photoprotection and pollutant adsorption with reduced sunscreen permeation |
5 | Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis |
6 | Prolonging the Half-Life of Histone Deacetylase Inhibitor Belinostat via 50 nm Scale Liposomal Subcutaneous Delivery System for Peripheral T-Cell Lymphoma Prolonging the Half-Life of Histone Deacetylase Inhibitor Belinostat via 50 nm Scale Liposomal Subcutaneous Delivery System for Peripheral T-Cell Lymphoma |
7 | 台灣冠狀動脈瘤處方型態評估 Prescribing patterns of coronary artery aneurysm in Taiwan |
8 | High Potency of SN-38-Loaded Bovine Serum Albumin Nanoparticles Against Triple-Negative Breast Cancer High Potency of SN-38-Loaded Bovine Serum Albumin Nanoparticles Against Triple-Negative Breast Cancer |
9 | Diminish the side effect of mitomycin C by using pH-sensitive liposomes: In vitro characterization and in vivo pharmacokinetics. Diminish the side effect of mitomycin C by using pH-sensitive liposomes: In vitro characterization and in vivo pharmacokinetics. |
10 | SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study |
11 | Microemulsion formulation design and evaluation for hydrophobic compound: Catechin topical application Microemulsion formulation design and evaluation for hydrophobic compound: Catechin topical application |
12 | UV filter entrapment in mesoporous silica hydrogel for skin protection against UVA with minimization of percutaneous absorption UV filter entrapment in mesoporous silica hydrogel for skin protection against UVA with minimization of percutaneous absorption |
13 | Development of pH-sensitive cationic PEGylated solid lipid nanoparticles for selective cancer-targeted therapy Development of pH-sensitive cationic PEGylated solid lipid nanoparticles for selective cancer-targeted therapy |
14 | 主動脈瘤流行病學及危險因子探討 Epidemiology and risk factors of coronary artery aneurysm in Taiwan: a population based case control study |
15 | Lipid-enveloped PLGA as a hybrid carrier for sustained delivering camptothecin in ovarian cancer. Lipid-enveloped PLGA as a hybrid carrier for sustained delivering camptothecin in ovarian cancer. |
16 | 三陰性乳癌臨床試驗概況淺談 Clinical Trials for Triple-negative Breast Cancer: recent results |
17 | What is the discrepancy between drug permeation into/across intact and diseased skins? Atopic dermatitis as a model What is the discrepancy between drug permeation into/across intact and diseased skins? Atopic dermatitis as a model |
18 | A msacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics A msacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics |
19 | Nanocarriers enhance the transdermal bioavailability of resveratrol:In-vitro and in-vivo studyMing Nanocarriers enhance the transdermal bioavailability of resveratrol:In-vitro and in-vivo study |
20 | - Mesoporous silica nanoparticles synthesized from LCD manufacturing extracts as a potential candidate for a drug delivery carrier: evaluation of their safety and biocompatibility. |
21 | - Percutaneous absorption and antibacterial activities of lipid nanocarriers loaded with dual drugs for acne treatment. |
22 | - Modification polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery. |
23 | - Modification polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery. |
24 | - Topical delivery of DNA oligonucleotide to induce p53 generation in the skin via thymidine dinucleotide (pTT)-encapsulated liposomal carrier. |
25 | - Tryptanthrin-loaded lipid nanoparticles for delivery into breast cancer cells: the effects of solid lipid/liquid lipid ratios in the inner core. |
26 | - Enhancement techniques for improving 5-aminolevulinic acid delivery through the skin. |
27 | - Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a psoriasis-like animal model using the CLSM technique to evaluate the penetration behavior |
28 | - Comparison of 5-aminolevulinic acid- encapsulated liposome vs. ethosome for skin delivery for photodynamic therapy. |
29 | - Comparison of 5-aminolevulinic acid- encapsulated liposome vs. ethosome for skin delivery for photodynamic therapy. |
30 | - Physicochemical and safety evaluation of 5-aminolevulinic acid in novel liposomes as carrier for skin delivery. |
31 | - In vitro percutaneous absorption and in vivo protoporphyrin IX accumulation in skin and tumors after topical 5-aminolevulinic acid application with enhancement using an erbium:YAG laser. |
32 | - Transdermal iontophoresis of 5- fluorouracil combined with electroporation and laser treatment. |
33 | - Enhancement of topical 5- aminolevulinic acid delivery by erbium:YAG laser and microdermabrasion. |
Project
NO |
YEAR — Source — No — Type
Project Name
|
Duration |
---|---|---|
1 |
113 — NK 高醫-中山合作計畫 — NK113P32 — 1 個人型
開發具有高角膜滲透性及房水部位控制釋放特性之交聯型聚乳酸奈米藥物眼藥水及其於糖尿病患者白內障治療之研究(Development of cross-linked polylactide-based eye drops exhibiting improved corneal permeability /controlled drug release at aqueous humor and their application in inhibiting cataracts of diabetic patients)
|
2024/01/01 ~ 2024/12/31 |
2 |
112 — NK 高醫-中山合作計畫 — — 1 個人型
開發具有高度組織液吸收能力之表面交聯型水溶性高分子奈米纖維及其應用於經皮藥物傳遞材料之研究(Developing surface cross-linked water-soluble nanofibers with a highly exudate adsorbing property for transdermal drug delivery)
|
2023/01/01 ~ 2023/12/31 |
3 |
109 — N 國科會(原科技部) — MOST109-2635-B-037-002 — 1 個人型
開發具診斷與治療用途之金包覆血清白蛋白奈米複合物遞送PXD101應用於惡性淋巴轉移( )
|
2020/08/01 ~ 2021/10/31 |
4 |
109 — X 高奇合作計畫 — 110CM-KMU-04 —
利用人類血清蛋白奈米顆粒攜帶SN-38應用於三陰性乳癌原位癌動物模式評估藥物動力學/藥效學與降低副作用之情形( )
|
2021/08/01 ~ 2022/07/31 |
5 |
109 — Z 大專學生研究計畫及博士後 — MOST110-2813-C-037-142-B — 8 大專學生研究計畫
110年度大專學生研究計畫-張庭瑜(生物3)( )
|
2021/07/01 ~ 2022/02/28 |
6 |
108 — M 高醫(種子計畫) — KMU-M109005 —
開發組織蛋白去乙醯酶抑制劑之標靶化奈米輸送系統應用於周邊T細胞淋巴瘤( )
|
2020/01/01 ~ 2020/12/31 |
7 |
107 — Z 大專學生研究計畫及博士後 — MOST108-2813-C-037-074-B — 8 大專學生研究計畫
108年度大專學生研究計畫-陳宇瑩(生物3)( )
|
2019/07/01 ~ 2020/02/29 |
8 |
107 — Z 大專學生研究計畫及博士後 — MOST108-2813-C-037-075-B — 8 大專學生研究計畫
108年度大專學生研究計畫-何錦瑞(藥學2)( )
|
2019/07/01 ~ 2020/02/29 |
9 |
106 — M 高醫(種子計畫) — KMU-M107019 —
以微酯體修飾中孔洞奈米矽球作為藥物傳遞系統載體之研究( )
|
2018/01/01 ~ 2018/12/31 |
10 |
105 — N 國科會(原科技部) — MOST105-2320-B-037-012 — 1 個人型
SN-38標靶抗癌藥物之臨床前試驗( )
|
2016/08/01 ~ 2017/07/31 |
11 |
104 — Q 新聘教師計畫(校內) — KMU-Q105004 —
具主動標靶與酸鹼敏感型微脂粒作為SN-38抗癌藥物之傳遞( )
|
2016/01/01 ~ 2016/12/31 |
12 |
104 — TP 頂尖計畫(高醫) — KMU-TP104PR18 —
坐骨神經壓迫誘導神經性疼痛和支持細胞活化的關聯性( )
|
2016/04/01 ~ 2016/09/30 |
13 |
103 — N 國科會(原科技部) — MOST103-2320-B-037-031 — 1 個人型
利用仿生紅血球隱匿奈米顆粒為載體進行網狀內皮系統標靶傳遞之研究( )
|
2014/08/01 ~ 2015/10/30 |
14 |
103 — Q 新聘教師計畫(校內) — KMU-Q104014 —
奈米複合載體攜帶喜樹鹼及其衍生物作為藥物傳輸載體之可行性評估( )
|
2015/01/01 ~ 2015/12/31 |